Objective The project, CARDIMMUN, aims to pursue development of the scientific findings from the FP6 project CVDImmune. Based on our patented discovery, that low levels of anti-PC (phosphorylcholine) indicate risk for future development of cardiovascular disease, we have developed both a diagnostic test (a marker to identify cardiovascular disease patients that are at high risk of secondary events) and a candidate drug - an innovative fully human monoclonal antibody antibody, PC-mAb - that can block vascular inflammation. Together, this forms a unique opportunity for a personalised medicine approach, with a companion diagnostic and a targeted intervention in an area that is still in great medical need, despite recent advances in therapy. PC-mAb is now ready for clinical development.The project will be progressed, by a structured plan that brings together SMEs and selected academic partners, and integrates preclinical and clinical studies into a commercially viable and mature therapeutic modality. The 5 work packages will embrace concept testing in animal models using biomarkers applicable also in human disease, coronary flow reserve and glucose uptake in inflamed arteries, as well as required toxicity studies. Additionally, studies in man are planned that explores safety, pharmacokinetics, pharmacodynamics and indices of clinical efficacy, including a placebo-controlled Proof of Activity trial in patients.Athera’s PC-mAb is targeting the market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. According to plan, the data will enable a business agreement with Athera and a partner (probably big pharma) to enter into larger scale clinical trials by early 2017. PC-mAb could then be launched on the market as a new drug, with clear block-buster potential, by year 2020. Fields of science medical and health sciencesclinical medicinecardiologycardiovascular diseasesmedical and health scienceshealth sciencespersonalized medicinemedical and health sciencesbasic medicinepharmacology and pharmacypharmacokinetics Programme(s) FP7-HEALTH - Specific Programme "Cooperation": Health Topic(s) HEALTH.2013.0-1 - Boosting the translation of health research projects' results into innovative applications for health Call for proposal FP7-HEALTH-2013-INNOVATION-2 See other projects for this call Funding Scheme CP-FP - Small or medium-scale focused research project Coordinator ACADEMISCH ZIEKENHUIS LEIDEN EU contribution € 278 320,00 Address ALBINUSDREEF 2 2333 ZA Leiden Netherlands See on map Region West-Nederland Zuid-Holland Agglomeratie Leiden en Bollenstreek Activity type Higher or Secondary Education Establishments Administrative Contact Jaco De Graaf (Mr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data Participants (4) Sort alphabetically Sort by EU Contribution Expand all Collapse all TURUN YLIOPISTO Finland EU contribution € 122 760,00 Address YLIOPISTONMAKI 20014 Turku See on map Region Manner-Suomi Etelä-Suomi Varsinais-Suomi Activity type Higher or Secondary Education Establishments Administrative Contact Mari Riipinen (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data ATHERA BIOTECHNOLOGIES AB Sweden EU contribution € 3 260 200,00 Address FOGDEVRETEN 2B 171 65 SOLNA See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Carina Schmidt (Mrs.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data CTC CLINICAL TRIAL CONSULTANTS AB Sweden EU contribution € 1 935 200,00 Address SVEAVAGEN 8 752 36 UPPSALA See on map Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Bengt Dahlström (Dr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data SMERUD MEDICAL RESEARCH INTERNATIONAL AS Norway EU contribution € 398 600,00 Address KARENSLYST ALLE 6 0278 Oslo See on map Region Norge Oslo og Viken Oslo Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Administrative Contact Knut Smerud (Mr.) Links Contact the organisation Opens in new window Website Opens in new window Total cost No data
